dc.contributor.author |
Masekela, Refiloe
|
|
dc.contributor.author |
Levin, M.
|
|
dc.contributor.author |
Annamalai, M.
|
|
dc.contributor.author |
Naidoo, V.
|
|
dc.contributor.author |
Van Niekerk, Andre
|
|
dc.contributor.author |
Hawarden, D.
|
|
dc.contributor.author |
Emanuel, S.
|
|
dc.contributor.author |
Katz, H.
|
|
dc.contributor.author |
Zar, Heather J.
|
|
dc.contributor.author |
Green, Robin J.
|
|
dc.contributor.author |
Kritzinger, F.E.
|
|
dc.contributor.author |
Manjra, Ahmed I.
|
|
dc.date.accessioned |
2018-11-29T04:55:09Z |
|
dc.date.available |
2018-11-29T04:55:09Z |
|
dc.date.issued |
2018-08 |
|
dc.description.abstract |
Although ˂5% of children with asthma suffer from severe asthma, they account for the highest use of health resources. The field of asthma
therapy is changing rapidly, with a number of new drugs and biologics being added to the treatment armamentarium, particularly for adults.
This, though, is not the case for paediatric patients, in whom a number of these novel molecules and drugs have not been investigated.
Even though adults have shown responses to medication in some studies, this does not necessarily imply that there will be similar results
in children. In the management of severe asthma, use of specific interventions to ensure treatment adherence and goal-setting for selfmanagement
is critical to ensure the best treatment outcomes. The objective of this article is to review and grade the current evidence base
for use of novel asthma drugs and to make evidence-based recommendations for their administration in children with severe asthma in the
South Africa context. We also review the evidence for medication-adherence strategies and self-management plans. |
en_ZA |
dc.description.department |
Paediatrics and Child Health |
en_ZA |
dc.description.librarian |
am2018 |
en_ZA |
dc.description.sponsorship |
SACAWG conducted a workshop, which received an unconditional
educational grant from the Allergy Society of South Africa – funded by
Novartis. |
en_ZA |
dc.description.uri |
http://www.samj.org.za |
en_ZA |
dc.identifier.citation |
Masekela, R., Levin, M., Jeena, P.M. et al. 2018, 'Looking beyond the magic bullet : novel asthma drugs or education, which works better?', South African Medical Journal, vol. 108, no. 8, pp. 619-623. |
en_ZA |
dc.identifier.issn |
0256-9574 (print) |
|
dc.identifier.issn |
2078-5135 (online) |
|
dc.identifier.other |
10.7196/SAMJ.2018.v108i8.13163 |
|
dc.identifier.uri |
http://hdl.handle.net/2263/67392 |
|
dc.language.iso |
en |
en_ZA |
dc.publisher |
Health and Medical Publishing Group |
en_ZA |
dc.rights |
© 2018, South African Medical Association. All rights reserved. This article is licensed under a Creative Commons Attribution-NonCommercial Works License (CC BY-NC 3.0). |
en_ZA |
dc.subject |
Children |
en_ZA |
dc.subject |
Asthma |
en_ZA |
dc.subject |
Therapy |
en_ZA |
dc.subject |
Drugs |
en_ZA |
dc.subject |
Omalizumab (OM) |
en_ZA |
dc.subject |
Tolerability |
en_ZA |
dc.title |
Looking beyond the magic bullet : novel asthma drugs or education, which works better? |
en_ZA |
dc.type |
Article |
en_ZA |